NVST (Envista Holdings Corporation Common stock, $0.01 par value per share)
Insider Trading Activity
Every open-market purchase and sale reported by NVST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Stefan Nilsson | President, Nobel Biocare | F | — | — |
| 2026-08-27 | Eric D. Hammes | Chief Financial Officer | F | — | — |
| 2026-08-27 | Robert Befidi | President, Diagnostics | F | — | — |
| 2026-08-27 | Veronica Acurio | President, Orthodontics | F | — | — |
| 2026-08-24 | Mischa Reis | SVP, Strategy & Bus. Dev. | Sell | — | — |
| 2026-08-20 | Eric D. Hammes | Chief Financial Officer | A | — | — |
| 2026-08-20 | Paul A Keel | Chief Executive Officer | A | — | — |
| 2026-05-27 | Paul A Keel | Chief Executive Officer | F | — | — |
| 2026-05-21 | R Scott Huennekens | Director | A | — | — |
| 2026-05-21 | Daniel Raskas | Director | A | — | — |
| 2026-05-21 | James Andrew Pierce | Director | A | — | — |
| 2026-05-21 | KIERAN GALLAHUE | Director | A | — | — |
| 2026-05-21 | Vivek Jain | Director | A | — | — |
| 2026-05-21 | CHRISTINE A TSINGOS | Director | A | — | — |
| 2026-05-21 | Wendy Carruthers | Director | A | — | — |
| 2026-02-27 | Robert Befidi | President, Diagnostics | MIXED | — | — |
| 2026-02-27 | Paul A Keel | Chief Executive Officer | MIXED | — | — |
| 2026-02-27 | Faez C Kaabi | Chief Accounting Officer | MIXED | — | — |
| 2026-02-27 | Mark E Nance | General Counsel | MIXED | — | — |
| 2026-02-27 | Mischa Reis | SVP, Strategy & Bus. Dev. | MIXED | — | — |
| 2026-02-27 | Stefan Nilsson | President, Nobel Biocare | MIXED | — | — |
| 2026-02-27 | Veronica Acurio | President, Orthodontics | MIXED | — | — |
| 2026-02-27 | Eric D. Hammes | Chief Financial Officer | MIXED | — | — |
| 2026-02-11 | Mischa Reis | SVP, Strategy & Bus. Dev. | MIXED | — | — |
| 2026-02-03 | Veronica Acurio | President, Orthodontics | A | — | — |
| 2026-02-03 | Faez C Kaabi | Chief Accounting Officer | A | — | — |
| 2026-02-03 | Mark E Nance | General Counsel | A | — | — |
| 2026-02-03 | Paul A Keel | Chief Executive Officer | A | — | — |
| 2026-02-03 | Eric D. Hammes | Chief Financial Officer | A | — | — |
| 2026-02-03 | Mischa Reis | SVP, Strategy & Bus. Dev. | A | — | — |
| 2026-02-03 | Robert Befidi | President, Diagnostics | A | — | — |
| 2025-11-04 | Paul A Keel | Chief Executive Officer | F | — | — |
| 2025-08-27 | Mischa Reis | SVP, Strategy & Bus. Dev. | Sell | — | — |
| 2025-08-27 | Veronica Acurio | President, Orthodontics | F | — | — |
| 2025-08-27 | Stefan Nilsson | President, Nobel Biocare | F | — | — |
| 2025-08-27 | Eric D. Hammes | Chief Financial Officer | F | — | — |
| 2025-08-27 | Robert Befidi | President, Diagnostics | F | — | — |
| 2025-07-16 | James Andrew Pierce | Director | A | — | — |
| 2025-06-12 | R Scott Huennekens | Director | A | — | — |
| 2025-06-12 | Barbara B. Hulit | Director | A | — | — |
| 2025-06-12 | CHRISTINE A TSINGOS | Director | A | — | — |
| 2025-06-12 | Wendy Carruthers | Director | A | — | — |
| 2025-06-12 | Vivek Jain | Director | A | — | — |
| 2025-06-12 | Daniel Raskas | Director | A | — | — |
| 2025-06-12 | KIERAN GALLAHUE | Director | A | — | — |
| 2025-05-27 | Paul A Keel | Chief Executive Officer | F | — | — |
| 2025-02-27 | Mark E Nance | General Counsel | MIXED | — | — |
| 2025-02-27 | Eric D. Hammes | Chief Financial Officer | A | — | — |
| 2025-02-27 | Robert Befidi | President, Diagnostics | MIXED | — | — |
| 2025-02-27 | Stefan Nilsson | President, Nobel Biocare | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 551,304 | — |
| — | Chief Executive Officer | 310,565 | — |
| — | Chief Financial Officer | 99,913 | — |
| — | Senior Vice President | 83,691 | — |
| — | Director | 82,105 | — |
| — | Director | 79,820 | — |
| — | SENIOR VICE PRESIDENT | 74,379 | — |
| — | General Counsel | 68,577 | — |
| — | President, Nobel Biocare | 61,560 | — |
| — | Director | 59,940 | — |
| — | Director | 59,930 | — |
| — | Chief Accounting Officer | 58,552 | — |
| — | Director | 54,010 | — |
| — | Director | 54,010 | — |
| — | Principal Financial Officer | 53,803 | — |
| — | SVP, Orthodontics | 53,223 | — |
| — | Director | 52,945 | — |
| — | President, Orthodontics | 48,806 | — |
| — | Chief Human Resources Officer | 46,759 | — |
| — | President, Diagnostics | 45,785 | — |
| — | Chief Financial Officer | 43,900 | — |
| — | Senior Vice President | 37,336 | — |
| — | Senior Vice President | 27,838 | — |
| — | SVP, Strategy & Bus. Dev. | 27,321 | — |
| — | VP & Chief Acct. Officer | 25,311 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVST quote page; the site-wide leaderboard is on the insider transactions hub.